Phytochemicals against COVID-19, Pharmacological Perspectives: A Systematic Review

Ahmed S. Ali a,b, Ekram A. Saied c*, Sharifa M. Theeban d#, Mazen M. Humayran e, Assmaa Ahmed Shaker f, Mohammed S. Almuhayawi g,h and Abdelbagi Alfadil g

a Department of Pharmacology, Faculty of Medicine, King Abdulaziz University, KSA.
b Department of Pharmaceutics, Faculty of Pharmacy, Assiut University, Egypt.
c Department of Clinical Pharmacy and Pharmacology, Ibn Sina National College for Medical Studies, Jeddah, KSA.
d Jeddah International College, Jeddah, KSA.
e Faculty of Medicine, Medical Intern at King Abdulaziz University Hospital/King Abdulaziz University, Jeddah, KSA.
f Ibn Sina National College for Medical Studies, Jeddah, KSA.
g Department of Medical Microbiology and Parasitology, Faculty of Medicine, King Abdulaziz University, Jeddah, KSA.
h Y. A. Jameel Scientific Chair of Prophetic Medical Applications, King Abdulaziz University, KSA.

Authors’ contributions

This work was carried out in collaboration among all authors. All authors read and approved the final manuscript.

Article Information

DOI: 10.9734/JPRI/2021/v33i53B33678

Editor(s):
(1) Dr. Fahmida Khan, National Institute of Technology Raipur, India.
(2) Dr. P. Veera Muthumari, V.V. Vanniaperumal College for Women, India.
(3) Dr. Sung-Kun Kim, Northeastern State University, USA.

Reviewers:
(1) Mark M. Alipio, Philippine Christian University, Philippines.
(2) Rajesh Kumar, Rajasthan University of Veterinary and Animal Sciences (RAJUVAS), India.
(3) A. Vijaya Anand, Bharathiar University, India.
(4) Veeresh Yadav, N.E.T. Pharmacy College, India.
(5) G. Bhuvaneshwari, Saveetha Institute of Medical and Technical Sciences, India.

Complete Peer review History, details of the editor(s), Reviewers and additional Reviewers are available here: https://www.sdiarticle5.com/review-history/76654

Received 29 October 2021
Accepted 29 November 2021
Published 06 December 2021

Lecturer;
MBBS Student;
*Corresponding author: E-mail: ekramnemr@ibnsina.edu.sa;
ABSTRACT

**Background:** Many publications discussed the potential role of medicinal plants in the management of COVID-19. However, clinical studies of the efficacy and safety of specified phytochemical(s) are limited.

**Objectives:** To explore the pharmacological profile of specified compounds against COVID-19

**Method:** Systematic literature search of academic databases to explore specified phytochemicals for the management of COVID-19 using appropriate search terms. Rayyan software was used to organize 786 citations of which, 236 articles were included in this review.

**Results:** Initially 70 compounds were identified to have a potential role in the management of COVID-19. In this review, 18 compounds were selected for further search

**Conclusion:** In vitro anti-SARS-CoV-2 activity has been demonstrated for a variety of natural compounds. However, preclinical research for most phytochemicals is scarce, and only a few compounds have been evaluated in clinical trials against COVID-19. A comprehensive pharmacological profile of these phytochemicals is urgently needed.

Keywords: Phytochemicals; COVID-19; SARS-CoV-2; flavonoids; alkaloids; essential oils.

1. INTRODUCTION

Coronavirus disease 2019 (COVID-19), which was first reported in Wuhan, China, in December 2019, is an ongoing global pandemic, highly infective respiratory viral illness. It is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It leads to extreme human and economic losses. As of 29 June 2021, more than 181 million cases have been identified, with more than 3.92 million confirmed deaths [1]. More details are available in these reviews [2-4]. The development of diagnostic tests, vaccinations, and medications for COVID-19 management has received a lot of attention [5].

Numerous meta-analyses have shown the potential beneficial role of medicinal plants in reducing the severity of COVID-19 when combined with standard pharmacological therapy [6-30]. Most clinical trials involved Chinese herbs [10, 12-15, 17, 18, 20, 22-29], few studies discussed the role of herbal medicine in specific countries, such as Nigeria [16] or India, [19]. Some clinical trials focused on a single plant or food as bee products [7, 11], plant-derived food-grade substances [21], Lianhua Qingwen (a Chinese herbal medicine) [28, 30]. However, it should be noted that integrated research on isolated phytochemicals (pure substances) is sparse, which may explain why most decision-makers are reluctant to study the efficacy and safety of phytochemicals in COVID-19 clinical studies. Therefore, the goal of this systemic review is to explore the potential role of phytochemicals in the management of COVID-19.

2. METHODS

Two databases were used, namely PubMed (NCBI). LitCOVID 19, last accessed in November 2021. The research was restricted to 2019-2021, full text, and English language. All citations were imported to endnote 8, duplicates were excluded. Rayyan program (for Systemic review) was used to organize and select the relevant articles [31]. PRISMA flow chart is shown in Fig. A [32].

The first objective was to identify phytochemical(s) for the management of COVID-19. The 2nd objective explores the efficacy and safety, pharmacology of specified phytochemicals. The study was conducted in two phases, search terms in phase one were: #1 "SARS-CoV-2" OR "COVID-19", "OR" coronavirus". #2: "Phytochemical" OR "medicinal plants", OR "herbal medicine" followed by advanced (combined) search: #1 AND#2. 70 compounds were identified to have potential activity against the coronavirus (Tables 1-3). 18 compounds were selected by two investigators: given their low IC_{50} against SARS-CoV-2, immunomodulating effect and good safety profile. Key terms in phase 2: each of the phytochemicals e.g. #3 Thymoquinone, 4 # clinical trial "OR" antiviral "OR" anti-inflammatory " OR "lung injury" OR "Pharmacokinetic" OR "Formulation" OR "safety". Followed by advanced search #3 AND #4.
Fig. A. PRISMA flow chart of the search for safety and efficacy of specified phytochemicals against COVID 19

*1- Only journals were included, 2- Only review articles, systemic reviews, clinical trials were included

Abbreviations and glossary of terms

ACE2 : Angiotensin converting enzyme-2.
ALI : Acute lung injury.
CPE : Cell-protective effects.
FDA : Food and Drug Administration.
IC$_{50}$/EC$_{50}$ values : The 50% inhibitory and effective concentration respectively.
LPS : Lipopolysaccharide.
M Wt. : Molecular weight.
Mpro : Main protease.
PK : Pharmacokinetics; describes absorption, distribution, metabolism, and elimination of drugs.
PLpro : Papain like proteases, and 3CLpro: 3-chymotrypsin like protease: enzymes essential for viral replication.
3. POTENTIAL ROLE OF PHYTO-CHEMICALS IN THE MANAGEMENT OF COVID-19

3.1 Overview

A comprehensive web-based resource for natural products (about 200 compounds) was launched in 2020 [33]. Several review articles included an extensive search for medicinal plant extracts, compounds that have been identified and proven to suppress the life cycle of the coronavirus. These reviews summarized the IC50, selectivity, mechanisms of action and structure of specified compounds as polyphenols [34-36], flavonoids [37,38] of which myricetin and scutellarin [39] were highlighted. Alkaloids [40,41] particularly lycorine [42,43] was of considerable interest, other alkaloids include tetrandrine, tangchinoline, cepharanthine [44] and reserpine [45]. Other classes of phytochemicals include: sterols [46], terpenoids [47,48], stilbenoid, resveratrol [49], triterpene glycoside (saponin) glycyrrhizin [50], and saponin (Aescin) [45]. Tannins (tannic acid), 3-isotheaflavin-3-gallate, theaflavin-3,3′-digallate [51], and essential oils [52-54].

Many publications provided an overview of the utility of phytochemicals against COVID-19 [55-57]. Some provided a detailed description of a specified compound(s) e.g., curcumin [58], valinomycin [59], tanshinones [60], resveratrol [61] and glycyrrhizin [62]; or plant e.g. *Nigella sativa* [63]. A non-comprehensive list (about 70 compounds) was provided in Tables 1-3. From this list, 18 compounds were selected for further search to explore their pharmacological profile (their structure is provided in Fig. 1). The selection was based on low IC50, immunomodulating effect and known safety profile by two authors.

![Thymoquinone](image)
![Lycorine](image)
![Glycyrrhizin](image)

![Resveratrol](image)
![Emodin](image)
![Aescin](image)

![Eugenol](image)
![Gingerol](image)
![Ginsenoside-Rb1](image)

![Eucalyptol](image)
![Cinnamaldehyde](image)
![Kaempferol](image)
Table 1. Compounds suggested interacting with the specified target(s) of SARS-CoV-2: Spike protein, 3CLpro or PLpro [33]

<table>
<thead>
<tr>
<th>Compound</th>
<th>Class/ source</th>
<th>mechanism</th>
</tr>
</thead>
<tbody>
<tr>
<td>Betulinic acid</td>
<td>Pentacyclic triterpenoid</td>
<td>3CLpro</td>
</tr>
<tr>
<td>Dihomo-γ-linolenic acid</td>
<td>ω−6 fatty acid</td>
<td>3CLpro</td>
</tr>
<tr>
<td>Dihydrotanshinone</td>
<td><em>Salvia miltiorrhiza</em></td>
<td>Spike protein</td>
</tr>
<tr>
<td>Tanshinonella</td>
<td><em>Salvia miltiorrhiza</em></td>
<td>PLpro and 3CLpro</td>
</tr>
<tr>
<td>Cryptotanshinone</td>
<td>Quinone</td>
<td>PLpro and 3CLpro</td>
</tr>
<tr>
<td>Lignan</td>
<td>Low M Wt. polyphenols</td>
<td>3CLpro</td>
</tr>
<tr>
<td>Moupinamide</td>
<td>A phenolic amide</td>
<td>PLpro</td>
</tr>
<tr>
<td>N-cis-feruloyl tyramine</td>
<td>A phenolic amide</td>
<td>PLpro and 3CLpro</td>
</tr>
<tr>
<td>Coumaroyl tyramine</td>
<td>A phenolic amide</td>
<td>PLpro and 3CLpro</td>
</tr>
<tr>
<td>Quercetin</td>
<td>Flavonol</td>
<td>PLpro and 3CLpro</td>
</tr>
<tr>
<td>Kaempferol</td>
<td>Flavonol</td>
<td>PLpro and 3CLpro</td>
</tr>
<tr>
<td>Sugiol</td>
<td>A diterpene</td>
<td>3CLpro</td>
</tr>
</tbody>
</table>

3.2 Pharmacological Profile of Selected Phytochemicals

Out of 18 selected phytochemicals (Fig. 1), two clinical trials were found, the 1st trial revealed that resveratrol, reduces angiotensin converting enzyme-2 (ACE2) expression in human adipose tissue [75]. The 2nd trial documented that, nанo-curcumin treatment is a promising technique for controlling inflammatory cytokines in COVID-19 patients [76]. Aescin (was registered in China and Italy for clinical trials to demonstrate its potential role as an adjuvant in the management of COVID-19 [77].

The following is a summary of what has been collected regarding the pharmacology profile of these compounds, with a focus on their potential role against COVID-19.
Table 2. Example of compounds with IC$_{50}$/EC$_{50}$ values tested against an infectious coronavirus [64]

<table>
<thead>
<tr>
<th>Compound</th>
<th>Chemical group</th>
<th>IC$<em>{50}$/EC$</em>{50}$ values</th>
<th>Coronavirus type targeted</th>
</tr>
</thead>
<tbody>
<tr>
<td>Glycyrrhizin</td>
<td>Saponin</td>
<td>EC$_{50}$ = 364.5 μM</td>
<td>SARS-CoV</td>
</tr>
<tr>
<td>Tetra-O-galloyl-β-D-glucose</td>
<td>Polyphenol</td>
<td>EC$_{50}$ = 4.5 μM</td>
<td>SARS-CoV</td>
</tr>
<tr>
<td>Luteolin</td>
<td>Flavonoid</td>
<td>EC$_{50}$ = 10.6 μM</td>
<td>SARS-CoV</td>
</tr>
<tr>
<td>Siniggin</td>
<td>Polyphenol</td>
<td>IC$_{50}$ = 217 μM</td>
<td>SARS-CoV</td>
</tr>
<tr>
<td>β-Sitosterol</td>
<td>Phytosterol</td>
<td>IC$_{50}$ = 1210 μM</td>
<td>SARS-CoV</td>
</tr>
<tr>
<td>Hesperetin</td>
<td>Flavonoid</td>
<td>IC$_{50}$ = 8.3 μM</td>
<td>SARS-CoV</td>
</tr>
<tr>
<td>Amentoflavone</td>
<td>Flavonoid</td>
<td>IC$_{50}$ = 8.3 μM</td>
<td>SARS-CoV</td>
</tr>
<tr>
<td>Luteolin</td>
<td>Flavonoid</td>
<td>IC$_{50}$ = 20.2 μM</td>
<td>SARS-CoV</td>
</tr>
<tr>
<td>Quercetin</td>
<td>Flavonoid</td>
<td>IC$_{50}$ = 23.8 μM</td>
<td>SARS-CoV</td>
</tr>
<tr>
<td>Isobavachalcone</td>
<td>Flavonoid</td>
<td>IC$_{50}$ = 7.3 μM</td>
<td>SARS-CoV</td>
</tr>
<tr>
<td>Psoralidin</td>
<td>Flavonoid</td>
<td>IC$_{50}$ = 4.2 μM</td>
<td>SARS-CoV</td>
</tr>
<tr>
<td>Tomentin A</td>
<td>Flavonoid</td>
<td>IC$_{50}$ = 6.2 μM</td>
<td>SARS-CoV</td>
</tr>
<tr>
<td>Tomentin B</td>
<td>Flavonoid</td>
<td>IC$_{50}$ = 6.1 μM</td>
<td>SARS-CoV</td>
</tr>
<tr>
<td>Tomentin E</td>
<td>Flavonoid</td>
<td>IC$_{50}$ = 5.0 μM</td>
<td>SARS-CoV</td>
</tr>
<tr>
<td>3’-O-Methyldiplocol</td>
<td>Flavonoid</td>
<td>IC$_{50}$ = 9.5 μM</td>
<td>SARS-CoV</td>
</tr>
<tr>
<td>Isoliquiritinigenin</td>
<td>Flavonoid</td>
<td>IC$_{50}$ = 61.9 μM</td>
<td>SARS-CoV</td>
</tr>
<tr>
<td>Kaempferol</td>
<td>Flavonoid</td>
<td>IC$_{50}$ = 116.3 μM</td>
<td>SARS-CoV</td>
</tr>
<tr>
<td>Kazinol F</td>
<td>Flavonoid</td>
<td>IC$_{50}$ = 43.3 μM</td>
<td>SARS-CoV</td>
</tr>
<tr>
<td>Broussochalcone B</td>
<td>Flavonoid</td>
<td>IC$_{50}$ = 57.8 μM</td>
<td>SARS-CoV</td>
</tr>
<tr>
<td>Papyril flavonol A</td>
<td>Flavonoid</td>
<td>IC$_{50}$ = 103.6 μM</td>
<td>SARS-CoV</td>
</tr>
<tr>
<td>Terrestrimine</td>
<td>Cinnamic amide</td>
<td>IC$_{50}$ = 15.8 μM</td>
<td>SARS-CoV</td>
</tr>
<tr>
<td>Blancoxanthone</td>
<td>Xanthone</td>
<td>EC$_{50}$ = 3 μg/ml</td>
<td>HCoV 229E</td>
</tr>
<tr>
<td>Pyranojacareubin</td>
<td>Xanthone</td>
<td>EC$_{50}$ = 15 μg/ml</td>
<td>HCoV 229E</td>
</tr>
<tr>
<td>Lycorine</td>
<td>Alkaloid</td>
<td>EC$_{50}$ = 15.7 IU/ml</td>
<td>SARS-CoV</td>
</tr>
<tr>
<td>Tingenone</td>
<td>Triterpene</td>
<td>IC$_{50}$ = 9.9 μM</td>
<td>SARS-CoV</td>
</tr>
<tr>
<td>Iguesterin</td>
<td>Triterpene</td>
<td>IC$_{50}$ = 2.6 μM</td>
<td>SARS-CoV</td>
</tr>
<tr>
<td>Pristimererin</td>
<td>Triterpene</td>
<td>IC$_{50}$ = 5.5 μM</td>
<td>SARS-CoV</td>
</tr>
<tr>
<td>Dihydrotanshineone I</td>
<td>Diterpene</td>
<td>IC$_{50}$ = 4.9 μM</td>
<td>SARS-CoV</td>
</tr>
<tr>
<td>Cryptotanshineone</td>
<td>Diterpene</td>
<td>IC$_{50}$ = 0.8 μM</td>
<td>SARS-CoV</td>
</tr>
<tr>
<td>Tanshinone IIA</td>
<td>Diterpene</td>
<td>IC$_{50}$ = 1.6 μM</td>
<td>SARS-CoV</td>
</tr>
<tr>
<td>Xanthoangelol</td>
<td>Chalcone</td>
<td>IC$_{50}$ = 11.4 μM</td>
<td>SARS-CoV</td>
</tr>
<tr>
<td>Hirsuteneone</td>
<td>Diarylheptanoid</td>
<td>IC$_{50}$ = 3.0 μM</td>
<td>SARS-CoV</td>
</tr>
<tr>
<td>Rubranside</td>
<td>Diarylheptanoid</td>
<td>IC$_{50}$ = 7.2 μM</td>
<td>SARS-CoV</td>
</tr>
<tr>
<td>Curcumin</td>
<td>Diarylheptanoid</td>
<td>IC$_{50}$ = 5.7 μM</td>
<td>SARS-CoV</td>
</tr>
<tr>
<td>Flt3 receptor-interacting lectin (FRIL).</td>
<td>Lectin</td>
<td>EC$_{50}$ = 6.25 μg/ml</td>
<td>SARS-CoV-2</td>
</tr>
<tr>
<td>Abrus precatorius (APA) Lectin</td>
<td>Lectin</td>
<td>EC$_{50}$ = 0.45 μg/ml</td>
<td>SARS-CoV</td>
</tr>
<tr>
<td>Urtica dioica agglutinin (UDA) Lectin</td>
<td>Lectin</td>
<td>EC$_{50}$ = 1.3 μg/ml</td>
<td>SARS-CoV</td>
</tr>
</tbody>
</table>

Other compounds are not listed above. Resveratrol, Emodin,Aescin, Ginsenoside-Rb1, Leptodacytione, Celastrol, Tetrandrine, Cepharanthine, S-aikosaponinB2, Quercetin-3-b-galactoside, Chalcones, Theaflavin, Myricetin, Scutellarein[40, 65-70].

Essential oils with potential antiviral and immunomodulating activity, 8-cineole (eucalyptol), allyl sulfide, farnesene, farnesol, nerolidol; eugenol, menthol, carvacrol, cinnamaldehyde [71-74]

3.2.1 Thymoquinone

It is a quinone compound found in the seeds of Nigella sativa (Ranunculaceae) It has a broad pharmacological activity, and a good safety profile [78]. Its potential role in the management of COVID-19 was suggested based on its antiviral activity and ability to attenuate lung injury and inflammation [79-82]. Thymoquinone has poor oral bioavailability [83] likely due to its low solubility in water. Pharmaceutical formulations and nano delivery systems were suggested to improve their bioavailability and distribution [84-86].

3.2.2 Lycorine

Lycorine is a phenanthidine alkaloid isolated from the bulbs of Lycoris radiata (Amaryllidaceae). It has broad pharmacological
activity [87], it has potent activity against SARS-CoV [42]. Its ability to suppress SARS-CoV-2 replication was confirmed in Vero-6 cells, the EC50 of lycorine, and chloroquine were, 0.18 and 1.36 µM, respectively, CC value >40 µM [69]. An animal study showed its very high volume of distribution and short half-life [88]. More, preclinical investigations are needed to determine other PK parameters such as protein binding and metabolism. Lycorine, in particular, has a wide range of pharmacological effects on a variety of disorders while having relatively low toxicity and minimal side effects [89].

3.2.3 Glycyrrhizin

It is triterpene glycoside (saponin), which is also known as glycyrrhizic acid isolated from the roots of Glycyrrhiza glabra (Fabaceae). It has several pharmacological activities [90]. The compound or its active metabolite expresses antiviral effects against SARS-CoV in cell culture [91]. In vitro studies demonstrated that glycyrrhizin potently neutralizes SARS-CoV-2 by inhibiting the viral main protease (Mpro) [92]. It exhibited anti-inflammatory potential by several mechanisms including suppression of several proinflammatory mediators [93]. Its low bioavailability, low volume of distribution suggest that it is not likely to achieve an effective antiviral concentration of glycyrrhizin in lung tissues by oral or IV administration of safe doses 150-300 mg/day. An advanced delivery system such as inhalation can be considered to enhance its access to lung tissues.

3.2.4. Aescin (escin)

It’s a blend of triterpene saponins extracted from the seeds of the horse chestnut tree; Aesculus Hippocastanum ( Sapindaceae). It has a high molecular weight [94]. It possesses antiviral and immunomodulatory activities [95]. It has been widely used in the treatment of traumatic induced oedema, and chronic venous insufficiency [96]. It was demonstrated to inhibit acute inflammation similar to corticosteroids [45]. Its EC50 against SARS-CoV was 6 µM [45]. Given these pharmacological characteristics; it was suggested to consider escin as an add-on therapy in acute lung injury (ALI) associated with severe COVID-19 infection [96]. Injection formulation was registered in China and Italy for clinical trials to treat patients with COVID-19 pneumonia [77]. Aescin is not absorbed orally (bioavailability<0.3%); likely due to extensive first-pass metabolism [97]. Aescin PK features were studied in rats following IV injection at dosages ranging from 0.5 to 2.0 mg/kg. The half-life of Aescin was about 7-12 hr., Vd: 3-6 L/Kg[97]. PK data in humans not available.

3.2.5 Resveratrol

Resveratrol, a polyphenol compound (3,5,4’- trihydroxystilbene) found in grapes; Vitis vinifera (Vitaceae); Mulberry or Morus nigra (Moraceae) and Peanuts or Arachis hypogaea (Fabaceae). It possesses antioxidant, antitumor, antiviral and free radical scavenging properties [98]. Among the seven drugs tested against HCoV-229E in vitro, resveratrol demonstrated a favourable antiviral effect (EC50 = 4.6 µM which was superior to two drugs namely lopinavir/ritonavir (EC50 = 8.8 µM), and Chloroquine (EC50 = 5 µM). Resveratrol has also the best selectivity index (SI) of 45.65 [70]. It showed the ability to attenuate lung injury in animal models [99]. In this context, studies documented its ability to reduce biomarkers of inflammation, tumor necrosis factor (TNF-α), and C-reactive protein [100].

Resveratrol has poor oral bioavailability due to extensive metabolism in the gastrointestinal tract (GIT) and liver. It has a very short half-life, but its active sulfate metabolites showed a half-life of about 8 hr. It was speculated that levels of resveratrol in serum after oral administration are not likely to achieve an effective antiviral level [99]. However, the optimized pharmaceutical formulation may solve this limitation e.g., nanotechnology-based formulations and liposomes [72,101]. Clinical studies showed favorable safety outcomes of resveratrol. A good safety profile was assured with doses up to 500 mg/d for 60 days [102]. Most reported adverse effects are mild GIT symptoms such as diarrhea [103]. However, an advanced delivery system is needed to improve its PK profile.

3.2.6 Emodin

Emodin (6-methyl-1,3,8-trihydroxyanthraquinone) is found in many plants such as Chinese rhubarb; Rheum palmatum (Polygonaceae) [104]. It has many effective preventive and therapeutic effects [105]. Emodin was demonstrated to block the binding of SARS-CoV spike protein binding to its ACE2 receptors, hence it is likely to block viral entry into host cells [66]. It is one of the top 16 network-predicted repurposed drugs against SARS-CoV and is suggested among drug combinations (loremifene
plus emodin) [106]. It is included among traditional Chinese medicine against viral infections [107]. Its ability to attenuate lung injury is well documented in an animal model [108]. In animal studies, it has poor oral bioavailability due to extensive metabolism by glucuronidation. Emodin can cause reproductive, liver, and kidney toxicity, especially after chronic use [109].

3.2.7 Ginsenoside-Rb1 (G-Rb1)

G-Rb1 appears to be most abundant in Panax quinquefolius (Araliaceae) (American Ginseng). Ginsenosides possesses a variety of potential health effects [110]. The ability of ginseng to attenuate experimentally induced lung injury are well documented and several mechanisms were suggested to explain its pharmacological effect [111]. Molecular docking analysis indicated that ginsenosides have the potential to inhibit the SARS-CoV-2 Mpro receptor [112]. Genesiodins have very low bioavailability after oral administration [113]. Several studies documented the feasibility of enhancing its bioavailability by adopting several pharmaceutical technology approaches [114, 115]. When ginseng extract was standardized at a concentration of 4 mg ginsenosides/100 mg capsule and given at a dose of up to 114 g ginsenoside/kg to humans for up to 12 weeks, no significant adverse effects were demonstrated [116].

3.2.8 Eugenol

It is a phenolic molecule (methoxy phenols, M Wt 164.2) found in several plants such as cinnamon Cinnamomum (Lauraceae), clove Syzygium aromaticum (Myrtaceae), Tulsi Ocimum tenuiflorum (Lamiaceae). The potential value of clove and eugenol against COVID-19 was suggested based on their antiviral, anti-inflammatory, and antithrombotic effects [117]. Docking analysis indicated the possible interaction of α-pinene and eugenol with SARS-CoV spike protein [118]. The ability of eugenol to attenuate experimentally acute induced lung injury was documented [68]. It is likely mediated by the inhibition of lipoxigenase and cyclooxygenase pathways [119].

In mice, eugenol was ready absorbed after oral administration. The mean plasma half-life was about 14 hrs. suggesting a potential accumulation of the drug following repeated administrations [120]. A good safety profile was demonstrated in animal toxicity studies [121]. It is generally recognized as safe by the food and drug administration (FDA) [122]. However, local hypersensitivity reaction was reported in dental practice [123]. Based on its pharmacology profile, it is strongly recommended for pre-clinical studies and clinical studies, optimized formulations to explore its utility in the management of respiratory viral infections.

3.2.9 Gingerol

Gingerol, (6-gingerol) is a phenolic compound found in fresh ginger, Zingiber officinale (Zingiberaceae). Pre-clinical in vitro and animal models documented a broad spectrum of therapeutic values [124]. The favorable impact of ginger and its active ingredients on the immune system are extensively studied, in vitro studies included; modulation of inflammatory cytokines levels [125], inhibition of lipopolysaccharide (LPS)-induced inflammatory responses in macrophages [126], the potential of the anti-inflammatory effect of some drugs such as paracetamol [127]. Other studies documented the therapeutic benefits in the management of allergic asthma and allergic rhinitis [128, 129]. Pharmacokinetic (PK) studies showed that, in general, is well absorbed orally and has good tissue distribution [130, 131]. A good safety profile was reported in clinical trials [132], several pharmaceutical nanotechnology approaches were suggested to enhance its systemic availability or distribution [133, 134].

3.2.10 Eucalyptol (1,8-cineole)

It is a cyclic ether and monoterpenoid, it controls airway mucus hypersecretion and asthma via anti-inflammatory cytokine inhibition. It is abundant in many Eucalyptus species (Myrtaceae) [135]. It has low toxicity (LD50 for rats 2.5 g/kg) [116]. It showed the ability to attenuate ALI in an animal model by different mechanisms [136, 137]. A comprehensive review of the ability of essential oil to suppress several respiratory viruses was studied by Wani et al. [138]. Eucalyptus essential oils have been used to treat a variety of respiratory diseases, including sinusitis, pharyngitis, and bronchitis. One of its active ingredients (1,8-cineole), showed smooth muscle relaxant effects [139]. Furthermore, investigations have shown that inhaling cineole has analgesic and anti-inflammatory properties, suggesting that it could be utilized to treat chronic obstructive pulmonary disease (COPD) and asthma [140]. Sharma et al. [141] used molecular docking to show that
eucalyptol (1,8-cineole) may bind to Mpro and suppress viral multiplication. Strong ionic, hydrogen bonds and hydrophobic interactions have been described in the eucalyptol/Mpro complexes.

Several investigations found that eucalyptus oil and its active component, eucalyptol, have strong immunomodulatory activities. They were able to reduce the release of pro-inflammatory cytokines from macrophages and monocytes while maintaining their phagocytic properties [142].

In conclusion, it has an anti-inflammatory, bronchodilator, antibacterial effect, mucolytic, and antiviral activity. It is well absorbed orally, can be inhaled, and has good lipophilicity which suggests adequate access to lung cells. It has a good safety profile; therefore, the compound is suggested for more investigations in the management of respiratory viral infections.

### 3.2.11 Cinnamaldehyde

Cinnamaldehyde is an active ingredient in the bark of Cinnamon trees *Cinnamomum verum* (*Lauraceae*). The essential oil of cinnamon bark contains >90% cinnamaldehyde (predominantly the Trans E- isomer) synthetic compound is also available. According to docking experiments, cinnamaldehyde may prevent SARC-CoV-2 from attaching to its target receptors [143]. Cinnamaldehyde’s preventive benefits in the animal model of ALI have been demonstrated [144]. Different mechanisms were demonstrated; including neutrophils, macrophages, and total cell number in bronchoalveolar lavage fluid is inhibited. It reduced the levels of inflammatory cytokines such as TNF-, interleukin (IL-6), IL-13, and IL-1 [145].

Cinnamaldehyde is approved by the FDA for use within allergenic percutaneous patch tests [146]. It has had a low potential for toxicity but weak sensitization reactions in animals and human skin allergy were reported [147]. It is metabolized to cinnamyl alcohol and methyl cinnamate and cinnamic acid, these compounds are potentially toxic [146]. In acute studies, these materials have a low to moderate order of oral toxicity (LD50 values of 1.5–39 g/kg body weight) [148].

About 52% of cinnamaldehyde is absorbed through the skin and shown to be rapidly absorbed from the gut. It is metabolized and excreted as polar metabolites, the final major urinary metabolite is hippuric acid [148]. Novel intravenous sub-micrometre emulsion showed good tissue distribution and enhanced antitumor efficacy without significant toxicity in an animal model of cancer [149].

### 3.2.12 Kaempferol (KMF)

Kaempferol (3,5,7-trihydroxy-2-(4-hydroxyphenyl)-4H-chromen-4-one) is a polyphenol abundant in fruits and vegetables, herbal medications, and beverages derived from plants. It's used to treat a variety of diseases [150]. Several studies suggested KMF has superior efficacy compared to many other natural compounds against SARS-CoV-2 [151,152].

KMF shares structural similarities with other flavonoids such as myricetin and dihydromyricetin, which showed strong inhibitory activity against the 3-chymotrypsin-like protease (3CLpro) of SARS-CoV-2 [153]. KMF was shown to inhibit MERS 3CLpro (IC50 = 35.3 μM) and SARS 3CLpro (IC50 = 116.3 μM) [154]. Molecular docking documented strong interaction of KMF with SARS-CoV-2 Mpro 3CLpro [155]. This finding was confirmed by another docking study, which also documented an inhibition rate of about 90% at a concentration of 62.5 μM cell protective effect (CPE) inhibition assay. The authors concluded that KMF was found to protect cells against virus-induced cell death, suggesting that it could be a promising SARS-CoV-2 antiviral treatment [151].

The ability of KMF to attenuate the experimentally induced lung injury are well documented, various mechanisms were suggested [156,157]. KMF is expected to show low bioavailability, therefore several studies suggested the utility of pharmaceutical approaches such as phospholipid complexes; solid dispersion, self-emulsifying formulation to enhance its bioavailability [158]. Nano formulations were also investigated to improve PK characteristics of KMF [159]. On the other hand, KMF was found to enhance the bioavailability of some drugs after oral administration [160].

### 3.2.13 Rutin

Rutin, (a glycoside) also known as rutoside or quercetin-3-O-rutinoside, is a citrus flavonoid found in a range of plants, including Citrus (*Rutaceae*) and Buckwheat or Fagopyrum esculentum (*Polygonaceae*) species [161]. Several computations and *in vitro* testing suggest its activity against SARS-CoV-2 [162,163].

Based
on the crystal structures of 3CLpro and RdRp, docking studies revealed that sulfate or glucuronide metabolite of rutin can inhibit these enzymes; which are essential for replication of SARS-CoV-2 [164]. Moreover, it demonstrated a good ability to attenuate experimentally induced ALI [165], and potent thrombolytic activity [166].

Before being absorbed into the circulation, rutinosides like rutin and nicotiflorin are deglycosylated and subsequently conjugated mostly with glucuronate and sulfate, which are the predominant forms in plasma [167]. Intravenous or intranasal administration was suggested to improve the delivery of ruin [164]. Despite several preclinical mechanistic studies on its anticancer activities, the lack of well-designed randomized clinical trials on ruin's safety and therapeutic activity highlights the need for greater clinical research [168].

3.2.14 Leptodactylone

It is a coumarin isolated from Leptodactylon pungens (Polemoniaceae) and Linanthus demissus (Polemoniaceae) species, [169]. In vitro study was applied in Vero-E6 cells infected by SARS-CoV and measured the CPE by fluorescence microscope revealed that it produced 60 % protection of the infected cells (EC %) at 100 micro mols [170]. PK and safety data of Leptodactylone are not available.

3.2.15 Celastrol

It is a pentacyclic triterpenoid (belong to triterpene quinine methides) extracted from Tripterygium wilfordii (Celastraceae) [171]. It has broad pharmacological activities [172]. Celastrol inhibits SARS-CoV-2 Mpro 3CLpro and acts as a superoxide radical scavenger, according to docking and other relevant studies [173]. Moreover, it showed promising in vivo results in animal models for inflammatory pulmonary diseases [174]. In rats, the pure compound showed poor bioavailability which improved after using an optimized tablet dosage form [175]. Several studies showed the utility of pharmaceutical techniques to enhance its PK characteristics [176,177]. However, liver and kidney induced toxicity was demonstrated in animal studies [178]. More studies are needed to clarify the safety concern.

3.2.16 Tetrandrine (TET)

It is a bis-benzylisoquinoline alkaloida calcium channel blocker. It is isolated from the plant Stephania tetrandra (Menispermaceae). It has immunomodulatory effects and was found to be beneficial against inflammation, and lung cancer in clinical trials, with a favorable safety profile. It was demonstrated as effective against Ebola virus, Mycobacterium TB, Plasmodium falciparum, and Candida albicans. Tetrandrine's pharmacological properties have been demonstrated by its effects on many signaling pathways, including, calcium channel, suppression of formation of reactive oxygen species, increased autophagy, reversal of multidrug resistance, and caspase pathway [179]. It was suggested to act against the coronavirus by antagonism of the two-pore channel 2 (TPC2) [180]. It also decreased human coronavirus strain OC43 (HCoV-OC43) infection of MRC-5 human lung cells in vitro, with an inhibitory concentration (IC50) of 0.33 μM/L [40]. It showed promising effects in the management of silicosis, and in one study it was given by inhalation to ameliorate lung fibrosis [181].

A published hypothesis, discussed in detail that TET can be considered a promising treatment for COVID-19. The research reviewed the multiple properties of the drug, including its ability to inhibit replication of related coronavirus at very low concentrations. Then, the researcher also discussed its PK and the possibility of achieving an effective concentration in lung tissue. They also reviewed the expected side effects; drug interactions and precautions to be considered in certain situations [180].

3.2.17 Pristimerin (Pris)

Pristimerin, a quinonoid triterpene, isolated from the Chinese herbal plant Tripterygium wilfordii (Celastraceae), and it has been claimed that pristimerin has anti-fungal, anti-oxidant, anti-bacterial, and antiviral characteristics [182,183]. It is active against SARS-CoV with an IC50 = 5.5 0.7 M According to several studies, pristimerin and its biological counterpart URB602 are monoglyceride lipase inhibitors, [184]. The formation of proteasomes was suppressed, NF-B activity and cyclin D1 expression were downregulated, and Bax, caspase, and cleavage of poly (ADP-ribose) polymerase PARP-1 were activated as part of pristimerin's anticancer activities [185]. Studies in animals showed that Pris has a half-life of about 2 hours and poor bioavailability of about 28 % after oral administration. It is primarily metabolized by phase I enzymes [186].
Table 3. Bioavailability of specified phytochemicals

<table>
<thead>
<tr>
<th>Phytochemicals</th>
<th>Oral route</th>
<th>Intravenously (IV)/ Intraperitoneal Route (IP)</th>
<th>Enhancer and notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Glycyrrhizin [209]</td>
<td>Extremely low</td>
<td>Sodium caprate &gt; sodium laurate &gt; sodium caprylate &gt; sodium oleate</td>
<td>Nasal-80-fold greater compared with oral administration. Rectal administration, greater compared with oral</td>
</tr>
<tr>
<td>Resveratrol [210, 211]</td>
<td>Preferred route</td>
<td>Dose-dependent. Low water solubility which explains its slow absorption.</td>
<td></td>
</tr>
<tr>
<td>Lycorine [88]</td>
<td>Not available</td>
<td>No significant difference between (IP, IV)</td>
<td>The concentration in plasma was undetectable, which indicate its rapid clearance</td>
</tr>
<tr>
<td>Emodin [109, 212]</td>
<td>Poor intestinal absorption, fast elimination, and low bioavailability.</td>
<td>Gender-dependent</td>
<td></td>
</tr>
<tr>
<td>Aescin [213]</td>
<td>Film-coated tablet with sustained-release allowed high bioavailability</td>
<td></td>
<td></td>
</tr>
<tr>
<td>G-RB1 [113]</td>
<td>The low oral bioavailability of RB1 and rapid reduction of Rg1 in blood indicated that pharmaceutical technology is necessary</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CELASTROL [175]</td>
<td>Tablets with enhanced bioavailability was reported</td>
<td>Gender-dependent</td>
<td></td>
</tr>
</tbody>
</table>
3.2.18 Curcumin

It is described as a drug with multitarget for multiple chronic diseases. It has broad pharmacological activity. Its potential role in the management of COVID-19 was suggested [187, 188]. Curcumin is a bright yellow chemical produced by plants of the Curcuma longa (Zingiberaceae) that could potentially block ACE2 to prevent COVID-19 entrance into host cells [189]. It also has a potential inhibitory effect on COVID-19 Mpro [190]. An in vitro study showed that treatment with cationic carbon dots based on curcumin can suppress coronavirus replication by stimulating the production of interferon-stimulating genes (ISGs) and cytokines (IL8 and IL6) of Vero cells by triggering the innate immunity of the host [191]. Curcumin has been shown to lower influenza A virus infection and its associated pneumonia. It suppresses virus-induced activation of several inflammatory pathways (TLR2/4, MAPK, and NFB). Given these findings, it was suggested that curcumin has a potential role in the treatment of COVID-19 induced lung complications [192]. Curcumin has anti-inflammatory and anti-fibrotic effects by several mechanisms [193]. Furthermore, in experimental models of lung fibrosis, curcumin has been demonstrated to decrease collagen formation [194]. A study showed that prophylactic application of curcumin decreased the inflammation and reduces the influx of fluid in the lungs of a rat model of induced hypoxia [195].

Curcumin has poor bioavailability and as such, it is not likely to show good tissue distribution. [196]. Some clinical trials suggested its good safety profile after oral administration [197]. However, it is considered unsafe for pregnant women. It can cause GIT side effects, and there are some reports of liver injury [198, 199].

3.2.19 Betulinic acid (BTA)

BTA is lupine-type pentacyclic triterpenoid saponin (3β-hydroxy-lup-20). It is found in the bark of several natural plants, primarily Betula pendula (Betulaceae). Its anti-inflammatory, anti-angiogenic, and immunomodulatory properties, as well as its anti-human immunodeficiency virus effects, have been demonstrated. The majority of studies focused on its anticancer effects and postulated the underlying mechanisms [200, 201]. BTA was discovered to be a strong inhibitor of (SARS-CoV) in vitro [202]. Molecular modelling analysis indicated that BTA interacts with coronavirus (SARS-CoV) 3CL protease [203]. Several studies suggested BTA ability to attribute experimentally induced lung injury by several mechanisms [204, 205]. BTA has very low water solubility that explains its low bioavailability. Some derivatives were suggested to improve its bioavailability while retaining its antitumor activity [206]. Other studies utilized pharmaceutical techniques such as liposomes, nanosuspension, nanoencapsulation analogue [5, 207] to improve its bioavailability. In animal experiments, a good safety profile was documented [208].

4. CONCLUSION

1) Many phytochemicals have been suggested to have potent anti-SARS-CoV-2 activity based on in vitro testing. However, preclinical research is sparse, and only a few compounds were tested in clinical trials against COVID-19.
2) Extensive research is needed to provide a full pharmacological profile of phytochemicals that showed promising efficacy against SARS-CoV-2.
3) The pharmacokinetics (PK) features of phytochemicals could be improved with pharmaceutical technologies. Table 3 summarizes the bioavailability of several substances as well as techniques to improve them.
4) Decision-makers, researchers, and pharmaceutical companies will benefit from this study.

CONSENT AND ETHICAL APPROVAL

This systematic review is approved by Ibn Sina National College for Medical Studies- Research Center (ISNC-RC) number 01CPP23112021.

COMPETING INTERESTS

Authors have declared that no competing interests exist.

REFERENCES


48. Chang F, et al., Anti-human coronavirus (anti-HCoV) triterpenoids from the leaves
72. Huang M, et al. Liposome co-encapsulation as a strategy for the delivery


Koushki M, Dashatan NA, Meshkani R. Effect of resveratrol supplementation on inflammatory markers: A systematic review and meta-analysis of randomized controlled trials. (1879-114X (Electronic)).


Cottart CH, Nivet-Antoine JL, V Fau -Beaudeux, Beaudeux JL. Review of recent data on the metabolism, biological effects, and toxicity of resveratrol in humans. (1613-4133 (Electronic)).

Agrawal DC et al. Medicinal plants and fungi: recent advances in research and development. Springer. (Electronic); 2017.

Cui Y et al. The pharmacology, toxicology and therapeutic potential of anthraquinone derivative emodin. (1875-5364 (Electronic)).


148. Panel TRE et al. A toxicologic and dermatologic assessment of related esters and alcohols of cinnamic acid and cinnamyl alcohol when used as fragrance ingredients. Food and Chemical Toxicology. 2007;45(1):S1-S23.


164. da Silva FMA et al. Flavonoid glycosides and their putative human metabolites as potential inhibitors of the SARS-CoV-2 main protease (Mpro) and RNA-dependent RNA polymerase (RdRp). Memórias do Instituto Oswaldo Cruz. 2020;115.


189. Utomo RY, Meiyyanto E. Revealing the potency of citrus and galangal constituents to halt SARS-CoV-2 infection; 2020.


199. Balaji S, Chempakam B. Toxicity prediction of compounds from turmeric (Curcuma longa L). Food and Chemical Toxicology. 2010;48(10):2951-2959.


209. Sasaki K et al. Improvement in the bioavailability of poorly absorbed glycyrrhizin via various non-vascular administration routes in rats. International


© 2021 Ali et al.; This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Peer-review history:
The peer review history for this paper can be accessed here:
https://www.sdiarticle5.com/review-history/76654